Selective inhibitor of T-type calcium channels (IC50
values are 270 and 310 nM for Cav
3.3 and Cav
3.2 respectively in a patch EP assay). Decreases burst activity in STN neurons; reduces cataleptic behaviour in an in vivo
rat model of Parkinson's disease. Displays no significant inhibition of L- or N-type calcium channels, Kir
) or KV
11.1 (hERG) potassium channels. Orally active.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
The discovery and characterization of ML218: A novel, centrally active T-type calcium channel inhibitor with robust effects in STN neurons and in a rodent model of Parkinson's disease.
Xiang et al.
ACS Chem.Neurosci., 2011;2:730
Lack of antiparkinsonian effects of systemic injections of the specific T-type calcium channel blocker ML218 in MPTP-treated monkeys.
Galvan et al.
ACS Chem.Neurosci, 2016;
The citations listed below are publications that use Tocris products. Selected citations for ML 218 hydrochloride include:
Showing Results 1 - 1 of 1